{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 3 Study of Fixed Dose Combinations of Fianlimab and Cemiplimab Versus Relatlimab and Nivolumab in Participants With Unresectable or Metastatic Melanoma","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-3-study-of-fixed-dose-combinations-of-fianlimab-and-cemiplimab-versus-relatlimab-and-nivolumab-in-participants-with-unresectable-or-metastatic-melanoma\/#breadcrumbitem"}]}